Pink SheetContract manufacturing of biologics is one of the few weak points in the typically overwhelming advantage the US holds over Europe in bestowing the first approval for new drug products, a Pink Sheet
In VivoAt SynBioBeta 2025, In Vivo spoke with several executives leading companies at the cutting edge of synthetic biology and techbio. These conversations revealed not just technological breakthroughs, b
ScripBefore life sciences companies reported first-quarter earnings, a jump in sales might have been expected as companies and patients stocked up ahead of tariffs. But in the event, this was less pronounc
ScripBiopharmaceutical companies raised just $13.1bn during the first quarter of 2025 – less than half of the $30.1bn raised in Q1 of 2024, the latest Financing Quarterly Statistics report from Biomedtra